This bill matters because it touches on healthcare affordability for some of the most vulnerable Americans and the system for developing drugs for rare conditions. If it becomes law, people on Medicaid could avoid higher out-of-pocket costs, making healthcare more accessible and reducing financial strain on low-income families. Without this bill, Medicaid recipients might face increased expenses for their medical care.

Additionally, the bill impacts the market for orphan drugs. By restoring their exclusion from Medicare price negotiation, it could encourage drug companies to invest in developing treatments for rare diseases, potentially benefiting patients with those conditions. However, it could also mean higher drug prices for Medicare, as the government would have less leverage to negotiate costs for those specific medications. If the bill doesn't pass, more orphan drugs could become subject to price negotiation, potentially leading to lower costs for Medicare but possibly altering incentives for drug development.